Risk factor
Considerable default risk
Profitability factor
Greatly overvalued vs peers
About
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of GKOS is 128 and suggests 14% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation s
Buy
Sell